2023
A pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Fineberg S, Choi E, Shapiro-Thompson R, Dhaliwal K, Neustadter E, Sakheim M, Null K, Trujillo-Diaz D, Rondeau J, Pittaro G, Peters J, Corlett P, Krystal J. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology 2023, 48: 991-999. PMID: 36804489, PMCID: PMC10209175, DOI: 10.1038/s41386-023-01540-4.Peer-Reviewed Original ResearchConceptsBorderline personality disorderSecondary outcome measuresOutcome measuresSocio-occupational functioningSuicidal ideationPilot studyTrial of ketaminePersonality disorderInfusion of ketaminePrimary outcome measureEffects of ketamineMidazolam groupAdverse eventsKetamine groupClinical benefitMood symptomsKetamineFDA approvalDrug midazolamInfusionBPD symptomsLarger studyDepressed moodSymptomsChronic mood
2017
Individuals with Borderline Personality Disorder show larger preferred social distance in live dyadic interactions
Fineberg SK, Leavitt J, Landry CD, Neustadter ES, Lesser RE, Stahl DS, Deutsch-Link S, Corlett PR. Individuals with Borderline Personality Disorder show larger preferred social distance in live dyadic interactions. Psychiatry Research 2017, 260: 384-390. PMID: 29248760, PMCID: PMC5972044, DOI: 10.1016/j.psychres.2017.11.054.Peer-Reviewed Original ResearchConceptsBorderline personality disorderPersonality disorderEtiology of BPDMental health conditionsSpecific symptomsNeural circuitsHealth conditionsLive dyadic interactionsRecovery status